NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what executives described as encouraging trends in two-year blinded data and a lower-than-anticipated major

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.